BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Repromedix Corp. Appoints Dr. Michael J. Burns Chief Executive Officer


7/17/2007 9:19:52 AM

National Reproductive Diagnostic Laboratory Positions for Continued Growth

WOBURN, MA--(MARKET WIRE)--Jul 17, 2007 -- Repromedix Corp., the leading national diagnostic laboratory for advanced reproductive testing, announced today that Dr. Michael J. Burns has been appointed Chief Executive Officer.

"We are delighted that we were able to attract Dr. Burns to Repromedix," said Jack Davis, Chairman of the Board. "With over 25 years' experience growing international pharmaceutical and healthcare companies, Dr. Burns brings extensive senior and general management experience in the critical areas of medical research and development, corporate and business development, product licensing and sales force delivery and marketing."

Dr. Burns comes to Repromedix after having served more than ten years as the President and Chief Operating Officer of Ferndale Laboratories, a leader in the manufacturing and marketing of pharmaceutical products and medical devices. Having joined Ferndale in 1992, Dr. Burns also served as the President of the company's Pharmaceutical Division and Vice President of Corporate Development. Prior to Ferndale, Dr. Burns held senior management and leadership positions with Yamanouchi Europe B.V., Smith, Kline & French Pharmaceuticals Ltd., and Napp Laboratories Ltd.

"The increasing number of women seeking to have children later in life has significantly contributed to the development of sophisticated and innovative diagnostic techniques in reproductive medicine," said Paul Kowalski, President and Vice President of Sales. "Repromedix has grown from a pioneer to national leader in infertility diagnostics. We look forward to leveraging Dr. Burns' industry experience and expertise as we continue to meet the growing need for valuable medical and genetic information that can contribute to the attainment of parenthood for so many."

"I couldn't be more excited to join the incredible team of infertility professionals at Repromedix," said Dr. Michael J. Burns. "I am especially attracted to Repromedix' decade-long passion for helping doctors help couples start families. I share deeply the company's entrepreneurial spirit, its commitment to excellence and its vision for future growth and medical partnership opportunities. I look forward to contributing to the company's continued growth and success."

A British native, Dr. Burns holds a postgraduate degree in Pharmacology from the University of Nottingham and an undergraduate degree from the University of Reading in Physiology, Biochemistry and Chemistry.

About Repromedix (www.repromedix.com)

Repromedix is the leading national diagnostic laboratory for advanced reproductive testing. By taking an interdisciplinary approach to clinical infertility testing that encompasses endocrinology, immunology and genetics, Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding complex problems of reproductive failure. Since its inception in 1995, the company has assisted more than 45,000 patients by conducting over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility and unexplained infertility.

Contact:

Contact: Lisa Scimemi Phone: 781-404-1752 Email: Email Contact

Source: Reprodmedix


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->